REGISTER FOR THE 2024 CONFERENCE
Shopping Cart

No products in the cart.

chemotherapy

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint...
๐Ÿ—“๏ธ 2024-12-16
Read MoreClinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer.

Patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) require complex management strategies. This study evaluated the prognostic significance of the perichemotherapy skeletal muscle index (SMI) and carbohydrate antigen 19-9 (CA 19-9) in patients with BRPC or LAPC...
๐Ÿ—“๏ธ 2024-11-23
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSkeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer.

Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line systemic therapy. We conducted a multicentre, prospective observational study and enrolled...
๐Ÿ—“๏ธ 2024-10-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreImpact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-naรฏve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received...
๐Ÿ—“๏ธ 2024-09-17
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFrequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

Effect of resistance training on physical function during chemotherapy in colon cancer.

The decline of physical function during chemotherapy predicts poor quality of life and premature death. It is unknown if resistance training prevents physical function decline during chemotherapy in colon cancer survivors. This multicenter trial randomly assigned 181 colon cancer survivors...
๐Ÿ—“๏ธ 2024-07-16
Read MoreEffect of resistance training on physical function during chemotherapy in colon cancer.

Cancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

This comprehensive review sheds light on cancer cachexia (CC), a significant condition marked by muscle wasting in cancer patients, emphasizing its molecular mechanisms and potential treatments. Highlighting the challenge CC presents, especially in older individuals, the article discusses the multifaceted approach needed to combat this syndrome.
๐Ÿ—“๏ธ January 2024
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreCancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!